Barriers to viral suppression in children aged 9 years or younger on dolutegravir-based antiretroviral therapy in Malawi, a mixed-methods study

By sjmartinez • May 31, 2025

Phiri K, Hagstrom C, Lungu E, Balakasi K, Songo J, Makwaya A, Smith D, Worku A, Hoffman R, Phiri S, Dovel K, van Oosterhout JJ. Barriers to viral suppression in children aged 9 years or younger on dolutegravir-based antiretroviral therapy in Malawi, a mixed-methods study. PLOS Glob Public Health. 2025 May 30;5(5):e0004510. doi: 10.1371/journal.pgph.0004510. PMID: 40445885; PMCID: PMC12124501.

Tags: Infectious Diseases, Publications

Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study

Emu B, Kumar PN, Mills A, Berhe M, Cash BR, Kuo KL, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with[...]

Estimated Burden of Coccidioidomycosis

Williams SL, Benedict K, Jackson BR, Rajeev M, Cooksey G, Ruberto I, Williamson T, Sunenshine RH, Osborn B, Oltean HN, Reik RR, Freedman MS, Spec[...]

Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]